# US 2015/0174113 A1 · Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0174113 A1
- Document ID: US20150174113A1
- Status: Published application
- Kind: A1
- Application number: 14/414,297
- Filed: 2013-07-16
- Published: 2015-06-25
- Earliest claimed: 2012-07-20
- Assignees: Bayer Pharma Aktiengesellschaft
- Applicants: Bayer Pharma Aktiengesellschaft
- Inventors: Walter Hübsch; Michael Hahn; Alexandros Vakalopoulos; Volkhart Min-Jian Li; Frank Wunder; Johannes-Peter Stasch; Karl-Heinz Schlemmer; Friederike Stoll; Niels Lindner; Eva Maria Becker-Pelster
- Web page: https://patentgrep.com/patent/US20150174113A1

## CPC

- A61K 31/45: having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/24: having an amino or nitro group
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/4015: having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A61K 31/415: 1,2-Diazoles
- A61K 31/421: 1,3-Oxazoles, e.g. pemoline, trimethadione
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- C07C 227/18: by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
- C07C 229/50: with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
- C07C 255/54: containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
- C07D 207/27: with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D 211/76: attached in position 2 or 6
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 263/22: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- C07C 2602/08: the other ring being five-membered, e.g. indane
- C07C 2602/10: the other ring being six-membered, e.g. tetraline
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present application relates to novel substituted aminoindane- and aminotetralinecarboxylic acids, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of cardiovascular and cardiopulmonary diseases.

## Claims

### Claim 1

Compound of the formula (I)
in which
n represents the number 1 or 2
and
A represents a group of the formula
in which
* denotes the respective point of attachment to the remainder of the molecule,
L1 represents straight-chain (C1-C5)-alkanediyl,
x represents the number 1, 2 or 3, where one of these CH2 groups may be replaced by —O—,
R1A and R1B independently of one another represent hydrogen or methyl,
L2 represents a bond or straight-chain (C1-C5)-alkanediyl,
Ar represents phenyl or 5- or 6-membered heteroaryl having up to three heteroatoms from the group consisting of N, O and S,
R2 represents a substituent selected from the group consisting of fluorine, chlorine, bromine, cyano, (C1-C4)-alkyl, trifluoromethyl, (C1-C4)-alkoxy and trifluoromethoxy,
p represents the number 0, 1 or 2,
where in the case where the substituent R2 occurs twice, its respective meanings can be identical or different,
L3 represents a bond, —O—, —CH2—, —CH2—CH2— or —CH═CH—
and
R3 and R4 independently of one another represent hydrogen or a substituent selected from the group consisting of fluorine, chlorine, bromine, cyano, (C1-C4)-alkyl, trifluoromethyl, (C1-C4)-alkoxy and trifluoromethoxy,
and their salts, solvates and solvates of the salts.

### Claim 2 (depends on 1)

Compound of the formula (I) according to claim 1 in which
n represents the number 1 or 2
and
A represents a group of the formula
in which
* denotes the respective point of attachment to the remainder of the molecule,
L1 represents straight-chain (C2-C4)-alkanediyl,
x represents the number 1 or 2, where one of these CH2 groups may be replaced by —O—,
L2 represents a bond or straight-chain (C1-C4)-alkanediyl,
Ar represents phenyl,
R2 represents a substituent selected from the group consisting of fluorine, chlorine, cyano, (C1-C4)-alkyl and trifluoromethyl,
p represents the number 0 or 1,
L3 represents a bond or —CH2—CH2—
and
R3 and R4 independently of one another represent hydrogen or a substituent selected from the group consisting of fluorine, chlorine, cyano, (C1-C4)-alkyl and trifluoromethyl,
and their salts, solvates and solvates of the salts.

### Claim 3 (depends on 1)

Compound of the formula (I) according to claim 1 in which
n represents the number 1 or 2
and
A represents a group of the formula
in which
* denotes the respective point of attachment to the remainder of the molecule
and
R2 represents methyl, ethyl, isopropyl or tert-butyl,
and their salts, solvates and solvates of the salts.

### Claim 4 (depends on 1)

Process for preparing a compound of the formula (I) as defined in claim 1, wherein a compound of the formula (II)
in which n has the meanings given in claim 1
and
T1 and T2 are identical or different and represent (C1-C4)-alkyl
is reacted in the presence of a base with a compound of the formula (III)
in which A has the meanings given in claim 1
and
X1 represents a leaving group, for example chlorine, bromine, iodine, mesylate, triflate or tosylate,
to give a compound of the formula (IV)
in which n, A, T1 and T2 each have the meanings given above,
and this is then converted by hydrolysis of the ester groupings —C(O)OT1 and —C(O)OT2 into the corresponding dicarboxylic acid of the formula (I)
and the resulting compounds of the formula (I) are optionally separated into the enantiomers and/or diastereomers thereof and/or optionally reacted with the appropriate (i) solvents and/or (ii) bases or acids to give the solvates, salts and/or solvates of the salts thereof.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 1)

Medicament comprising a compound as defined in claim 1 in combination with one or more inert, nontoxic, pharmaceutically suitable excipients.

### Claim 9 (depends on 1)

Medicament comprising a compound as defined in claim 1 in combination with one or more further active compounds selected from the group consisting of organic nitrates, NO donors, cGMP-PDE inhibitors, stimulators of guanylate cyclase, antithrombotic agents, hypotensive agents and lipid metabolism modifiers.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

Method for treatment and/or prevention of heart failure, angina pectoris, hypertension, pulmonary hypertension, thromboembolic disorders, ischaemias, vascular disorders, impaired microcirculation, renal insufficiency, fibrotic disorders and arteriosclerosis in humans and animals by administration of an effective amount of at least one compound as defined in claim 1 to a human or animal in need thereof.

### Claim 12 (depends on 8)

A method for the treatment and/or prevention of heart failure, angina pectoris, hypertension, pulmonary hypertension, thromboembolic disorders, ischaemias, vascular disorders, impaired microcirculation, renal insufficiency, fibrotic disorders and arteriosclerosis in humans and animals by administration of an effective amount of the medicament of claim 8 to a human or animal in need thereof.

### Claim 13 (depends on 9)

A method for the treatment and/or prevention of heart failure, angina pectoris, hypertension, pulmonary hypertension, thromboembolic disorders, ischaemias, vascular disorders, impaired microcirculation, renal insufficiency, fibrotic disorders and arteriosclerosis in humans and animals by administration of an effective amount of the medicament of claim 9 to a human or animal in need thereof.
